Tag: pharma law


What role does the NHMRC play in clinical trials in Australia?

As a preview to some of the issues that will be discussed in our upcoming 9th Annual Pharmaceutical Law, Reform & Regulation Conference, we spoke with Samantha Robertson, Executive Director, Evidence, Advice and Governance Branch, NHMRC to discuss the Good Practice Process for site assessment and authorisation of clinical trials. 1. Can you tell us…

27 Aug 2016, by Informa Insights


Rare cancers: Measuring success in small doses

Rare cancers "is a term which encompasses both rare and less common cancers. A rare cancer is defined as a type of cancer that has less than 6 incidences per year per 100,000 population. A less common cancer is defined as one that has between 6 and 12 incidences per year per 100,000 population" (Cancer…

10 Feb 2015, by Informa Insights


Pharmaceutical industry slams impact of Commission of Audit

The recently released National Commission of Audit has been met with hostile reception from the healthcare industry, particularly from the pharmaceutical sector, as its recommendations threaten to further complicate an already complex profession. According to a May 1 statement from the Pharmaceutical Society of Australia (PSA), one of the recommendations of the Commission of Audit…

12 May 2014, by Informa Insights


EU Commission fighting anticompetitive agreements in pharmaceuticals

Harald Mische is an official at the European Commission’s Directorate General for Competition, where he currently forms part of the team in charge with antitrust enforcement in the pharma sector. He will be presenting at the 2014 Pharmaceutical Law conference, to be held on the 29-30 May in Sydney about competitive law enforcement in the…

18 Mar 2014, by Informa Insights